| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7887845 | JANSSEN R AND D | Antiviral compositions |
Mar, 2019
(5 years ago) | |
|
US7887845 (Pediatric) | JANSSEN R AND D | Antiviral compositions |
Sep, 2019
(4 years ago) | |
| US8003789 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(4 years ago) | |
| US6878717 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(4 years ago) | |
|
US8003789 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(4 years ago) | |
|
US6878717 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(3 years ago) | |
| US7037917 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Dec, 2020
(3 years ago) | |
|
US7037917 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Jun, 2021
(2 years ago) | |
Intelence is owned by Janssen R And D.
Intelence contains Etravirine.
Intelence has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Intelence are:
- US7887845
- US7887845*PED
- US8003789
- US6878717
- US8003789*PED
- US6878717*PED
- US7037917
- US7037917*PED
Intelence was authorised for market use on 26 March, 2012.
Intelence is available in tablet;oral dosage forms.
Intelence can be used as combo w/ other antiretrovirals for tx of hiv-1 in antiretroviral tx-experienced pt 6 years up, who have evidence of viral replication and hiv-1 strains resistant to non-nucleoside reverse transcriptase inhibitor and other antiretrovirals, in combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-experienced adult patients, who have evidence of viral replication and hiv-1 strains resistant to an nnrti and other antiretroviral agents.
Drug patent challenges can be filed against Intelence from 16 January, 2021.
The generics of Intelence are possible to be released after 16 January, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 16, 2022 |
| New Patient Population(NPP) | Mar 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2013 |
Drugs and Companies using ETRAVIRINE ingredient
NCE-1 date: 16 January, 2021
Market Authorisation Date: 26 March, 2012
Treatment: Combo w/ other antiretrovirals for tx of hiv-1 in antiretroviral tx-experienced pt 6 years up, who have evidence of viral replication and hiv-1 strains resistant to non-nucleoside reverse transcriptas...
Dosage: TABLET;ORAL
INTELENCE family patents
